Default company panoramic image

CamNutra Ltd

Build scientific base for ‘tomato pill’ Ateronon (heart health) through Cambridge and Harvard clinical trials and then market it strongly.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Cambridge, England, GB
  • Currency GBP
  • Website

Company Summary

Lycopene greatly reduces the risk of stroke, Ateronon has it in a highly bioavailable form. Camnutra will finish Cambridge and Harvard clinical trials to obtain highly credible scientific support and will then be very well placed to obtain top-level media coverage to generate product awareness. The market for supplements, where protection against heart disease is dominant, is some £400m in the UK, and the world market is at least 20 times this.


  • Default avatar
    Alf Lindberg

    Extensive scientific experience at Stanford University; Karolinska Institute; Head of R&D at Wyeth Vaccines, USA and Aventis Pasteur. Author of more than 300 original scientific papers. Between 1985 and 1993 he was a member of the Nobel Assembly and its Nobel Committee and member Board of Directors of the Nobel Foundation.

  • Default avatar
    Tim Dye

    Tim, proposed NED, served as CEO of William Ransom & Son plc. from September 1999 to January 2008, leading its transformation into one of the UK's largest natural healthcare groups. A serial entrepreneur, he has founded and run businesses in wireless technology, environmental management, automated meter reading and property development. He served as a NED of Abcam Ltd. from July 2006 to October 2011.
    Tim has a degree in Economics from Cambridge

  • Default avatar
    Nigel Iskander

    Nigel has very wide experience in dealing with media/communications with national media at the top level.
    In 1986 he founded the UK’s largest independent press agency (NTI) now merged with SWNS, where he is a director, to form £4m Group. At NTI he negotiated with the Foreign & Commonwealth Office to partner for media coverage of G8 and G20 summits and other major events.

  • Default avatar
    Eddie Powell

    Gained a PhD at Cambridge and then trained as an accountant with KPMG in London. Between 1982 and 2000 he was finance director at Marconi Instruments and Colt Group. He joined Abcam in 2000 and was instrumental in its IPO in 2005 before retiring in 2007.